Veracyte, Inc. (VCYT)
NASDAQ: VCYT · IEX Real-Time Price · USD
20.33
+0.20 (0.99%)
May 2, 2024, 2:02 PM EDT - Market open
Veracyte Revenue
In the year 2023, Veracyte had annual revenue of $361.05M with 21.76% growth. Revenue in the quarter ending December 31, 2023 was $98.20M with 22.29% year-over-year growth.
Revenue (ttm)
$361.05M
Revenue Growth
+21.76%
P/S Ratio
4.19
Revenue / Employee
$443,007
Employees
815
Market Cap
1.53B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
Dec 31, 2019 | 120.37M | 28.36M | 30.82% |
Dec 31, 2018 | 92.01M | 20.06M | 27.87% |
Dec 31, 2017 | 71.95M | 6.87M | 10.55% |
Dec 31, 2016 | 65.09M | 15.58M | 31.48% |
Dec 31, 2015 | 49.50M | 11.31M | 29.62% |
Dec 31, 2014 | 38.19M | 16.31M | 74.51% |
Dec 31, 2013 | 21.88M | 10.26M | 88.20% |
Dec 31, 2012 | 11.63M | 8.98M | 339.62% |
Dec 31, 2011 | 2.65M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
National HealthCare | 1.14B |
InMode | 492.05M |
Dynavax Technologies | 232.28M |
LeMaitre Vascular | 193.48M |
Ardelyx | 124.46M |
Protagonist Therapeutics | 60.00M |
VCYT News
- 9 days ago - Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 - Business Wire
- 10 days ago - New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance - Business Wire
- 16 days ago - Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 - Business Wire
- 2 months ago - Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines - Business Wire
- 2 months ago - Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results - Business Wire
- 2 months ago - Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference - Business Wire
- 3 months ago - Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 - Business Wire
- 3 months ago - Veracyte Completes Acquisition of C2i Genomics - Business Wire